Evaluation of PPARγ agonists on rodent endothelial cell proliferation

Toxicology

Volumn 287, Issue 1-3, 2011, Pages 91-98

  Kakiuchi Kiyota, Satoko ^a,b   Arnold, Lora L ^a   Yokohira, Masanao ^a,c   Suzuki, Shugo ^a,d   Pennington, Karen L ^a   Cohen, Samuel M ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b PFIZER INC   (United States)

^c KAGAWA UNIVERSITY   (Japan)

^d NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Endothelial cell proliferation; Hemangiosarcoma; Pioglitazone; PPAR agonist; Rodent; Troglitazone

Indexed keywords

KI 67 ANTIGEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE;

ADIPOSE TISSUE; ANGIOSARCOMA; ANIMAL EXPERIMENT; ARTICLE; BIOASSAY; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

ADIPOSE TISSUE; ANIMALS; APOPTOSIS; BODY WEIGHT; CELL PROLIFERATION; CHROMANS; DNA; ENDOTHELIAL CELLS; FEMALE; HEPATOCYTES; MICE; ORGAN SIZE; PPAR GAMMA; RATS; RATS, WISTAR; THIAZOLIDINEDIONES;

MUS; RATTUS; RODENTIA;

EID: 79960700881     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2011.05.019     Document Type: Article

References (34)

1. Actos Drug Approval Package. Pharmacological Review Part 7. U.S. Food and Drug Administration Internet Website: http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/021073A_Actos_phrmr_P7.pdf.
2. Ades E.W., Candal F.J., Swerlick R.A., George V.G., Summers S., Bosse D.C., Lawley T.J. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J. Invest. Dermatol. 1992, 99:683-690.
3. Aoki T. Current status of carcinogenicity assessment of peroxisome proliferator-activated receptor agonists by the US FDA and a mode-of-action approach to the carcinogenic potential. J. Toxicol. Pathol. 2007, 20:197-202.
4. Berger J., Moller D.E. The mechanisms of action of PPARs. Annu. Rev. Med. 2002, 53:409-435.
5. Bonofiglio D., Aquila S., Catalano S., Gabriele S., Belmonte M., Middea E., Qi H., Morelli C., Gentile M., Maggiolini M., Ando S. Peroxisome proliferator-activated receptor-gamma activates p53 gene promoter binding to the nuclear factor-kappaB sequence in human MCF7 breast cancer cells. Mol. Endocrinol. 2006, 20:3083-3092.
6. Breider M.A., Gough A.W., Haskins J.R., Sobocinski G., de la Iglesia F.A. Troglitazone-induced heart and adipose tissue cell proliferation in mice. Toxicol. Pathol. 1999, 27:545-552.
7. Cao Y. Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases. Nat. Rev. Drug Discov. 2010, 9:107-115.
8. Chojkier M. Troglitazone and liver injury: in search of answers. Hepatology 2005, 41:237-246.
9. Cohen S.M., Ellwein L.B. Cell proliferation in carcinogenesis. Science 1990, 249:1007-1011.
10. Cohen S.M., Ellwein L.B. Genetic errors, cell proliferation, and carcinogenesis. Cancer Res. 1991, 51:6493-6505.
11. Drew R.T., Boorman G.A., Haseman J.K., McConnell E.E., Busey W.M., Moore J.A. The effect of age and exposure duration on cancer induction by a known carcinogen in rats, mice, and hamsters. Toxicol. Appl. Pharmacol. 1983, 68:120-130.
12. Duddy S.K., Parker R.F., Bleavins M.R., Gough A.W., Rowse P.E., Gorospe S., Dethloff L.A., de la Iglesia F.A. p53 is not inactivated in B6C3F1 mouse vascular tumors arising spontaneously or associated with long-term administration of the thiazolidinedione troglitazone. Toxicol. Appl. Pharmacol. 1999, 156:106-112.
13. El Hage, J., 2005. Toxicity profiles of peroxisome proliferator-activated receptor (PPAR) agonists and preclinical safety profile for muraglitazar (presentation). U.S. Food and Drug Administration Internet Website: http://www.fda.gov/default.htm.
14. Fukumura D., Ushiyama A., Duda D.G., Xu L., Tam J., Krishna V., Chatterjee K., Garkavtsev I., Jain R.K. Paracrine regulation of angiogenesis and adipocyte differentiation during in vivo adipogenesis. Circ. Res. 2003, 93:e88-e97.
15. Greenfield R.E., Ellwein L.B., Cohen S.M. A general probabilistic model of carcinogenesis: analysis of experimental urinary bladder cancer. Carcinogenesis 1984, 5:437-445.
16. Hardisty J.F., Elwell M.R., Ernst H., Greaves P., Kolenda-Roberts H., Malarkey D.E., Mann P.C., Tellier P.A. Histopathology of hemangiosarcomas in mice and hamsters and liposarcomas/fibrosarcomas in rats associated with PPAR agonists. Toxicol. Pathol. 2007, 35:928-941.
17. Hausman G.J., Poulos S.P., Pringle T.D., Azain M.J. The influence of thiazolidinediones on adipogenesis in vitro and in vivo: potential modifiers of intramuscular adipose tissue deposition in meat animals. J. Anim. Sci. 2008, 86:E236-E243.
18. Hellstrom A., Perruzzi C., Ju M., Engstrom E., Hard A.L., Liu J.L., Albertsson-Wikland K., Carlsson B., Niklasson A., Sjodell L., LeRoith D., Senger D.R., Smith L.E. Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:5804-5808.
19. Herman J.R., Dethloff L.A., McGuire E.J., Parker R.F., Walsh K.M., Gough A.W., Masuda H., de la Iglesia F.A. Rodent carcinogenicity with the thiazolidinedione antidiabetic agent troglitazone. Toxicol. Sci. 2002, 68:226-236.
20. Jaeschke H. Troglitazone hepatotoxicity: are we getting closer to understanding idiosyncratic liver injury?. Toxicol. Sci. 2007, 97:1-3.
21. Jat P.S., Noble M.D., Ataliotis P., Tanaka Y., Yannoutsos N., Larsen L., Kioussis D. Direct derivation of conditionally immortal cell lines from an H-2Kb-tsA58 transgenic mouse. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:5096-5100.
22. Kakiuchi-Kiyota S., Vetro J.A., Suzuki S., Varney M.L., Han H.Y., Nascimento M., Pennington K.L., Arnold L.L., Singh R.K., Cohen S.M. Effects of the PPARgamma agonist troglitazone on endothelial cells in vivo and in vitro: differences between human and mouse. Toxicol. Appl. Pharmacol. 2009, 237:83-90.
23. Kakiuchi-Kiyota S., Arnold L.L., Koza-Taylor P., Suzuki S., Cohen S.M. Analysis of peroxisome proliferator activated receptor gamma (PPARγ) agonist troglitazone-induced transcriptional changes in mouse endothelial cells. The Toxicologist 2011, 120(Suppl. 2).
24. Langley R.R., Ramirez K.M., Tsan R.Z., Van Arsdall M., Nilsson M.B., Fidler I.J. Tissue-specific microvascular endothelial cell lines from H-2K(b)-tsA58 mice for studies of angiogenesis and metastasis. Cancer Res. 2003, 63:2971-2976.
25. Lyrica Drug Approval Package Pharmacological Review (NDA-021446). U.S. Food and Drug Administration Internet Website: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021446_Lyrica%20Capsules_pharmr.PDF.
26. Ma Q.L., Yang T.L., Yin J.Y., Peng Z.Y., Yu M., Liu Z.Q., Chen F.P. Role of insulin-like growth factor-1 (IGF-1) in regulating cell cycle progression. Biochem. Biophys. Res. Commun. 2009, 389:150-155.
27. Martin R.A., Daly A., DiFonzo C.J., de la Iglesia F.A. Randomization of animals by computer program for toxicity studies. J. Environ. Pathol. Toxicol. Oncol. 1986, 6:143-152.
28. Moraes L.A., Piqueras L., Bishop-Bailey D. Peroxisome proliferator-activated receptors and inflammation. Pharmacol. Ther. 2006, 110:371-385.
29. Nesto R.W., Bell D., Bonow R.O., Fonseca V., Grundy S.M., Horton E.S., Le Winter M., Porte D., Semenkovich C.F., Smith S., Young L.H., Kahn R. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004, 27:256-263.
30. Ohnishi T., Arnold L.L., Clark N.M., Wisecarver J.L., Cohen S.M. Comparison of endothelial cell proliferation in normal liver and adipose tissue in B6C3F1 mice, F344 rats, and humans. Toxicol. Pathol. 2007, 35:904-909.
31. Pollak M.N., Schernhammer E.S., Hankinson S.E. Insulin-like growth factors and neoplasia. Nat. Rev. Cancer 2004, 4:505-518.
32. Steiner G., Cahill G.F. Brown and white adipose tissue metabolism response to norepinephrine and insulin. Am. J. Physiol. 1966, 211:1325-1328.
33. Suh N., Wang Y., Williams C.R., Risingsong R., Gilmer T., Willson T.M., Sporn M.B. A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis. Cancer Res. 1999, 59:5671-5673.
34. Wei M., Arnold L., Cano M., Cohen S.M. Effects of co-administration of antioxidants and arsenicals on the rat urinary bladder epithelium. Toxicol. Sci. 2005, 83:237-245.